The ontogeny of 3,4-dihydroxyphenylacetic acid in human cerebrospinal fluid.
Measurement of cerebrospinal fluid (CSF) levels of the minor dopamine metabolite 3,4-dihydroxyphenylacetic acid in neonates and children indicates that a rapid decline (approximately 90%) occurs in the first 2 years of life. The much less rapid ontogenetic decline seen for the predominant dopamine metabolite, homovanillic acid (HVA), indicates that differing factors affect CSF levels of the two acid metabolites. Further study is required to determine which compound more closely reflects ontogenetic changes in dopamine functioning.
Anderson
G M
GM
Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06510.
Riddle
M A
MA
Hoder
E L
EL
Feibel
F C
FC
Shaywitz
B A
BA
Cohen
D J
DJ
D015102:3,4-Dihydroxyphenylacetic Acid / Q000134:cerebrospinal fluid*; D002657:Child Development; D002675:Child, Preschool; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D007223:Infant; D007231:Infant, Newborn / Q000134:cerebrospinal fluid*; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D012016:Reference Values
D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D006719:Homovanillic Acid